Immunocore Holdings PLC Sponsored ADR $IMCR Shares Bought by Fiera Capital Corp

Fiera Capital Corp raised its position in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 1.0% during the 2nd quarter, Holdings Channel reports. The firm owned 813,074 shares of the company’s stock after buying an additional 7,924 shares during the quarter. Fiera Capital Corp’s holdings in Immunocore were worth $25,514,000 as of its most recent filing with the SEC.

Other institutional investors have also recently modified their holdings of the company. T. Rowe Price Investment Management Inc. boosted its position in Immunocore by 5.2% in the first quarter. T. Rowe Price Investment Management Inc. now owns 7,051,818 shares of the company’s stock valued at $209,228,000 after buying an additional 351,610 shares during the last quarter. Primecap Management Co. CA boosted its holdings in shares of Immunocore by 0.4% in the 1st quarter. Primecap Management Co. CA now owns 2,678,650 shares of the company’s stock valued at $79,476,000 after acquiring an additional 10,100 shares during the last quarter. Baker BROS. Advisors LP increased its stake in shares of Immunocore by 53.3% in the first quarter. Baker BROS. Advisors LP now owns 2,322,656 shares of the company’s stock worth $68,913,000 after acquiring an additional 807,338 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Immunocore by 0.4% during the first quarter. Massachusetts Financial Services Co. MA now owns 460,751 shares of the company’s stock worth $13,670,000 after purchasing an additional 1,706 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. raised its holdings in shares of Immunocore by 176.9% during the first quarter. Frazier Life Sciences Management L.P. now owns 301,170 shares of the company’s stock worth $8,936,000 after purchasing an additional 192,408 shares during the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Immunocore

In other Immunocore news, insider David M. Berman sold 22,532 shares of the stock in a transaction on Friday, September 12th. The shares were sold at an average price of $35.67, for a total transaction of $803,716.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 10.40% of the stock is currently owned by insiders.

Immunocore Stock Performance

NASDAQ IMCR opened at $35.37 on Friday. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of -62.05 and a beta of 0.78. Immunocore Holdings PLC Sponsored ADR has a twelve month low of $23.15 and a twelve month high of $39.33. The stock has a 50-day moving average of $33.95 and a 200 day moving average of $33.30. The company has a current ratio of 6.00, a quick ratio of 5.97 and a debt-to-equity ratio of 0.99.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Thursday, November 6th. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.32. Immunocore had a negative return on equity of 7.67% and a negative net margin of 7.70%.The business had revenue of $135.80 million during the quarter, compared to the consensus estimate of $137.29 million. During the same period in the prior year, the company posted $0.17 EPS. The business’s quarterly revenue was up 29.2% on a year-over-year basis. Sell-side analysts anticipate that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IMCR has been the topic of several analyst reports. Wells Fargo & Company began coverage on Immunocore in a research report on Friday, October 31st. They set an “overweight” rating and a $60.00 price target on the stock. Guggenheim initiated coverage on Immunocore in a report on Thursday, September 18th. They set a “neutral” rating on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research report on Wednesday, October 8th. Wall Street Zen upgraded Immunocore from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, Jefferies Financial Group started coverage on shares of Immunocore in a research note on Monday, August 25th. They set a “buy” rating and a $48.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.00.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.